Cargando…

Small-Molecule Inhibitor Leads of Ribosome-Inactivating Proteins Developed Using the Doorstop Approach

Ribosome-inactivating proteins (RIPs) are toxic because they bind to 28S rRNA and depurinate a specific adenine residue from the α-sarcin/ricin loop (SRL), thereby inhibiting protein synthesis. Shiga-like toxins (Stx1 and Stx2), produced by Escherichia coli, are RIPs that cause outbreaks of foodborn...

Descripción completa

Detalles Bibliográficos
Autores principales: Pang, Yuan-Ping, Park, Jewn Giew, Wang, Shaohua, Vummenthala, Anuradha, Mishra, Rajesh K., McLaughlin, John E., Di, Rong, Kahn, Jennifer Nielsen, Tumer, Nilgun E., Janosi, Laszlo, Davis, Jon, Millard, Charles B.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063779/
https://www.ncbi.nlm.nih.gov/pubmed/21455295
http://dx.doi.org/10.1371/journal.pone.0017883
_version_ 1782200829723279360
author Pang, Yuan-Ping
Park, Jewn Giew
Wang, Shaohua
Vummenthala, Anuradha
Mishra, Rajesh K.
McLaughlin, John E.
Di, Rong
Kahn, Jennifer Nielsen
Tumer, Nilgun E.
Janosi, Laszlo
Davis, Jon
Millard, Charles B.
author_facet Pang, Yuan-Ping
Park, Jewn Giew
Wang, Shaohua
Vummenthala, Anuradha
Mishra, Rajesh K.
McLaughlin, John E.
Di, Rong
Kahn, Jennifer Nielsen
Tumer, Nilgun E.
Janosi, Laszlo
Davis, Jon
Millard, Charles B.
author_sort Pang, Yuan-Ping
collection PubMed
description Ribosome-inactivating proteins (RIPs) are toxic because they bind to 28S rRNA and depurinate a specific adenine residue from the α-sarcin/ricin loop (SRL), thereby inhibiting protein synthesis. Shiga-like toxins (Stx1 and Stx2), produced by Escherichia coli, are RIPs that cause outbreaks of foodborne diseases with significant morbidity and mortality. Ricin, produced by the castor bean plant, is another RIP lethal to mammals. Currently, no US Food and Drug Administration-approved vaccines nor therapeutics exist to protect against ricin, Shiga-like toxins, or other RIPs. Development of effective small-molecule RIP inhibitors as therapeutics is challenging because strong electrostatic interactions at the RIP•SRL interface make drug-like molecules ineffective in competing with the rRNA for binding to RIPs. Herein, we report small molecules that show up to 20% cell protection against ricin or Stx2 at a drug concentration of 300 nM. These molecules were discovered using the doorstop approach, a new approach to protein•polynucleotide inhibitors that identifies small molecules as doorstops to prevent an active-site residue of an RIP (e.g., Tyr80 of ricin or Tyr77 of Stx2) from adopting an active conformation thereby blocking the function of the protein rather than contenders in the competition for binding to the RIP. This work offers promising leads for developing RIP therapeutics. The results suggest that the doorstop approach might also be applicable in the development of other protein•polynucleotide inhibitors as antiviral agents such as inhibitors of the Z-DNA binding proteins in poxviruses. This work also calls for careful chemical and biological characterization of drug leads obtained from chemical screens to avoid the identification of irrelevant chemical structures and to avoid the interference caused by direct interactions between the chemicals being screened and the luciferase reporter used in screening assays.
format Text
id pubmed-3063779
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-30637792011-03-31 Small-Molecule Inhibitor Leads of Ribosome-Inactivating Proteins Developed Using the Doorstop Approach Pang, Yuan-Ping Park, Jewn Giew Wang, Shaohua Vummenthala, Anuradha Mishra, Rajesh K. McLaughlin, John E. Di, Rong Kahn, Jennifer Nielsen Tumer, Nilgun E. Janosi, Laszlo Davis, Jon Millard, Charles B. PLoS One Research Article Ribosome-inactivating proteins (RIPs) are toxic because they bind to 28S rRNA and depurinate a specific adenine residue from the α-sarcin/ricin loop (SRL), thereby inhibiting protein synthesis. Shiga-like toxins (Stx1 and Stx2), produced by Escherichia coli, are RIPs that cause outbreaks of foodborne diseases with significant morbidity and mortality. Ricin, produced by the castor bean plant, is another RIP lethal to mammals. Currently, no US Food and Drug Administration-approved vaccines nor therapeutics exist to protect against ricin, Shiga-like toxins, or other RIPs. Development of effective small-molecule RIP inhibitors as therapeutics is challenging because strong electrostatic interactions at the RIP•SRL interface make drug-like molecules ineffective in competing with the rRNA for binding to RIPs. Herein, we report small molecules that show up to 20% cell protection against ricin or Stx2 at a drug concentration of 300 nM. These molecules were discovered using the doorstop approach, a new approach to protein•polynucleotide inhibitors that identifies small molecules as doorstops to prevent an active-site residue of an RIP (e.g., Tyr80 of ricin or Tyr77 of Stx2) from adopting an active conformation thereby blocking the function of the protein rather than contenders in the competition for binding to the RIP. This work offers promising leads for developing RIP therapeutics. The results suggest that the doorstop approach might also be applicable in the development of other protein•polynucleotide inhibitors as antiviral agents such as inhibitors of the Z-DNA binding proteins in poxviruses. This work also calls for careful chemical and biological characterization of drug leads obtained from chemical screens to avoid the identification of irrelevant chemical structures and to avoid the interference caused by direct interactions between the chemicals being screened and the luciferase reporter used in screening assays. Public Library of Science 2011-03-24 /pmc/articles/PMC3063779/ /pubmed/21455295 http://dx.doi.org/10.1371/journal.pone.0017883 Text en This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
spellingShingle Research Article
Pang, Yuan-Ping
Park, Jewn Giew
Wang, Shaohua
Vummenthala, Anuradha
Mishra, Rajesh K.
McLaughlin, John E.
Di, Rong
Kahn, Jennifer Nielsen
Tumer, Nilgun E.
Janosi, Laszlo
Davis, Jon
Millard, Charles B.
Small-Molecule Inhibitor Leads of Ribosome-Inactivating Proteins Developed Using the Doorstop Approach
title Small-Molecule Inhibitor Leads of Ribosome-Inactivating Proteins Developed Using the Doorstop Approach
title_full Small-Molecule Inhibitor Leads of Ribosome-Inactivating Proteins Developed Using the Doorstop Approach
title_fullStr Small-Molecule Inhibitor Leads of Ribosome-Inactivating Proteins Developed Using the Doorstop Approach
title_full_unstemmed Small-Molecule Inhibitor Leads of Ribosome-Inactivating Proteins Developed Using the Doorstop Approach
title_short Small-Molecule Inhibitor Leads of Ribosome-Inactivating Proteins Developed Using the Doorstop Approach
title_sort small-molecule inhibitor leads of ribosome-inactivating proteins developed using the doorstop approach
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063779/
https://www.ncbi.nlm.nih.gov/pubmed/21455295
http://dx.doi.org/10.1371/journal.pone.0017883
work_keys_str_mv AT pangyuanping smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach
AT parkjewngiew smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach
AT wangshaohua smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach
AT vummenthalaanuradha smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach
AT mishrarajeshk smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach
AT mclaughlinjohne smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach
AT dirong smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach
AT kahnjennifernielsen smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach
AT tumernilgune smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach
AT janosilaszlo smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach
AT davisjon smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach
AT millardcharlesb smallmoleculeinhibitorleadsofribosomeinactivatingproteinsdevelopedusingthedoorstopapproach